Get the Stockscreener App
85.15
1.33%
1.12
After Hours:
85.20
0.05
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $85.15, with a volume of 9.43M.
It is up +1.33% in the last 24 hours and up +6.40% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$84.03
Open:
$84.34
24h Volume:
9.43M
Relative Volume:
0.70
Market Cap:
$212.69B
Revenue:
$63.43B
Net Income/Loss:
$16.42B
P/E Ratio:
13.12
EPS:
6.49
Net Cash Flow:
$14.72B
1W Performance:
+1.31%
1M Performance:
+6.40%
6M Performance:
-10.11%
1Y Performance:
-25.77%
1-Day Range:
$84.00
$85.55
1-Week Range:
$82.82
$85.55
52-Week Range:
$73.31
$119.38
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
85.15 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
756.28 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.50 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
220.22 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.70 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Clark Capital Management Group Inc. Has $1.98 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by New England Asset Management Inc. - MarketBeat
Britain defends investment record as Merck scraps labs over pharma environment - MarketScreener
Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan - MSN
Merck & Co. Withdrawal Seen As Warning Of UK’s Declining Attractiveness - insights.citeline.com
Ex-Dividend Reminder: Gilead Sciences, Thermo Fisher Scientific and Merck - Nasdaq
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Chil - PharmiWeb.com
Merck's pneumococcal shot shows promise in at-risk children and teens - Reuters
Merck scraps £1 billion London research hub, citing U.K. investment issues By Investing.com - Investing.com
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees - BioSpace
Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister - uk.finance.yahoo.com
Merck's pneumococcal shot shows promise in children and teens in study - Reuters
Woodline Partners LP Has $68.62 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck Scraps Plans for £1 Billion London Hub in Fresh Blow to UK - Bloomberg.com
Merck says trial data for pneumonia shot Capvaxive shows promise in younger people - Seeking Alpha
Legacy Advisory Services LLC Invests $403,000 in Merck & Co., Inc. $MRK - MarketBeat
Merck's pneumococcal shot shows promise in late-stage study - MarketScreener
Nearwater Capital Markets Ltd Purchases New Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Signature Estate & Investment Advisors LLC - MarketBeat
Merck axes £1B London lab, calls UK 'uninvestable', threatening 125 jobs - International Business Times UK
Scientech Research LLC Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Jacobs Levy Equity Management Inc. Sells 34,822 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 - Stocktwits
Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’ - uk.finance.yahoo.com
Merck & Co., Inc. $MRK Holdings Trimmed by Nippon Life Global Investors Americas Inc. - MarketBeat
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? - Stocktwits
Merck to scrap London drug research centre - Reuters
Merck Pulls The Plug On London Research Center - Finimize
Merck manager’s awkward whispers didn’t constitute harassment, judge rules - HR Dive
US pharma giant Merck ditches plan for $1.4-bn research centre in UK - Citizen Tribune
Gotham Asset Management LLC Reduces Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck to cancel London drug research center, lay off scientists : FT - MSN
Helping protect against vaccine-preventable diseases - Merck.com
Merck halts U.K. research operations and bails on new facility in London - statnews.com
Merck closes £1B London research hub - breakingthenews.net
Merck plans to discontinue discovery research operations in UK - MarketScreener
Merck to scrap $1.35 billion London drug research centre, FT reports - MarketScreener
Merck scraps 1 billion pounds London drug research centre in blow to UK growthFT - MarketScreener
Merck slams UK as it scraps £1bn London drug research centre - Financial Times
31,963 Shares in Merck & Co., Inc. $MRK Bought by Caxton Associates LLP - MarketBeat
Ascent Group LLC Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Great Lakes Advisors LLC Increases Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
RNC Capital Management LLC Has $35.34 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Voleon Capital Management LP Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Jones Financial Companies Lllp - MarketBeat
Ashton Thomas Private Wealth LLC Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Closes $6 Billion Notes Offering - TipRanks
Merck Avoids Liability for Supervisor Whispering in Worker’s Ear - Bloomberg Law News
Daiichi Sankyo/Merck’s I-Dxd Tipped For Fast Track After Lung Cancer Results - insights.citeline.com
WCLC 2025: Merck-Daiichi’s ADC posts a phase II win in lung cancer - BioWorld MedTech
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):